Brief: TNF Pharmaceuticals Files For Offering Of 65.1 Mln Shares Of Common Stock
Brief: MyMD Pharmaceuticals Rebrands To New Name TNF Pharmaceuticals Inc
Brief: MyMD Pharmaceuticals Appoints Mitchell Glass As President And Chief Medical Officer
Brief: Mymd Pharmaceuticals Secures Strategic Investments
Brief: Mymd Pharmaceuticals Increases Number Of Directors To Seven From Six
Brief: MyMD Pharmaceuticals Says Co Regained Compliance With Nasdaq Minimum Bid Price Requirement For Continued Listing
Brief: MyMD Pharmaceuticals Announces Reverse Stock Split To Maintain Nasdaq Listing
MyMD Pharma up on positive mid-stage trial data for muscle loss disorder drug
Brief: MyMd Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug
Brief: MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
Brief: MyMD Announces Preclinical Study Results Showing Supera-CBD Reduced Acute Inflammatory Pain
Brief: FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application For Phase 2 Study Of Oral Tnf-Α Inhibitor Mymd-1
Brief: MyMD Pharmaceuticals Reports Positive Topline Phase 2 Results Oral TNF-Α Inhibitor
Brief: Mymd Pharmaceuticals Inc Awaits Receipt Of Data From Phase 2 Trial For MYMD-1
Brief: Mymd Pharma Provides Update On Phase 2 Trial Of Therapy For Delaying Aging And Extending Healthy Lifespan
Brief: Mymd Pharmaceuticals® And Charles River Present Positive Data For Next Generation, Oral Tnf-Α Inhibitor Mymd-1® In Rheumatoid Arthritis
Brief: MyMD Pharmaceuticals Joins LOT Network
Brief: MyMD Says U.S. DEA Has Determined That Supera-Cbd Is Not A Controlled Substance Or Listed Chemical
Brief: MyMD Announces $15 Mln Offering With Existing Investors